Crohn DiseasePhase 4ProRAPIDNCT05552287
Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease
A Phase 4 study testing Infliximab in people with Crohn Disease and Child, Only, run by Erasmus Medical Center at 1 site in Netherlands.
Trial summary
Rationale: Crohn's disease (CD) is a chronic, debilitating inflammatory bowel disease (IBD) which is diagnosed during childhood in up to one in ten patients. The use of anti-tumor necrosis factor (TNF)-α agents has significantly ameliorated CD management. Read more about this study
- Who is it for?
- Ages 1 year to 15 years
- Conditions the study is for
- Crohn Disease, Child, Only, Biologic; Inadequate
- What is being tested?
- Infliximab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteNetherlands
- Study dates
- 2 Aug 2023to Aug 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 15 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Anti-TNF-α naïve children (age 1-15 years) with CD and an indication to start IFX treatment will be eligible for inclusion after a diagnosis of CD is made based on the Porto criteria. Indications of starting IFX treatment as per ECCO-ESPGHAN guidelines include non-response after induction with exclusive enteral nutrition or steroids, non-response to immunomodulators, severe growth delay, extensive disease and/or structuring or penetrating disease, with or without perianal disease. Evaluation of the indication to start IFX is performed at the discretion of the attending physician.
Who cannot join
- Established monogenetic IBD
- Diagnosis with UC or IBD-U, ulcerative colitis like
- Active fistulizing/perianal disease at start of IFX treatment (patients with inactive fistulizing/perianal disease are allowed to participate)
- Severe comorbidity (not related to IBD)
- Immediate need for surgery (i.e., symptomatic stenosis or stricture in the bowel)
- Severe infection such as sepsis or opportunistic infections, positive tuberculin test or a chest radiograph consistent with tuberculosis or malignancy
Show all 10Show fewer
- Pregnancy, suspected or definitive
- Treatment with anti-TNF or other biological drugs in the past
- Start of corticosteroids or mesalazine less than 2 weeks prior to first IFX infusion
- Start of Exclusive Enteral Nutrition less than 2 week prior to first IFX infusion
Trial locations and contacts
1 site in 1 country.
Netherlands1 site, 1 recruiting
- Recruiting
Erasmus Medical Center
Rotterdam, 3015 GD
Lissy de Ridder, MD, PhD, l.deridder@erasmusmc.nl
Lissy de Ridder, MD, PhD
About this study
Official title: Prospective Analysis of Pharmacokinetic Infliximab Data in Pediatric CD Patients (ProRAPID)
Rationale: Crohn's disease (CD) is a chronic, debilitating inflammatory bowel disease (IBD) which is diagnosed during childhood in up to one in ten patients. The use of anti-tumor necrosis factor (TNF)-α agents has significantly ameliorated CD management. Infliximab (IFX) is the first anti-TNF-α agent registered for pediatric CD. The current dosing recommendation of IFX is extrapolated from adult studies, and it is a weight-based dose (5 mg/kg) delivered during induction (infusion at weeks 0, 2, and 6) and maintenance (every 8 weeks). However, pediatric patients have a 25-40% lower drug exposure compared to adults, particularly children under 10 years of age, resulting in diminished efficacy and an increased risk of developing a complicated disease course. The investigators hypothesize that an intensified IFX induction scheme (instead of the current dosing recommendation) is more effective in the treatment of pediatric CD patients.
Objective: The primary study objective of our study is to assess the efficacy of an IFX intensified induction scheme vs. a standard dosing schedule in improving drug exposure without treatment escalation in pediatric CD patients. Secondary objectives are clinical and biochemical remission without treatment escalation, development of antibodies to IFX (ATI) and adverse reactions.
Read more
Study design: An international, multicenter, prospective, open-label trial. Study population: Anti-TNF-α naïve children (age 1-15 years) with CD and an indication to start IFX treatment.
Intervention: IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion. Follow-up will continue for the duration of the study (week 24).
Main endpoint: Proportion of patients with IFX TL ≥ 5 µg/mL at week 12 without treatment escalation.
Read the detailed description
INTRODUCTION AND RATIONALE
Definition of the problem
Crohn's disease (CD) is a chronic, debilitating inflammatory bowel disease (IBD) which is diagnosed during childhood in up to one in ten patients. Pediatric CD patients often have more severe and extensive disease compared to adults. Prospective studies in pediatric CD are scarce; therefore, many questions remain unanswered in the treatment of pediatric CD. The discovery of anti-tumor necrosis factor (TNF)-α agents opened up a new window in the pharmacological management of this condition. Infliximab (IFX) was the first anti-TNF-α agent to be approved for use in the treatment of CD. Several clinical studies showed its efficacy in inducing mucosal healing and improving long-term outcomes, even as a first-line treatment. Efficacy of IFX has been related to IFX trough levels, which are dependent on clearance of IFX. Lower IFX trough levels (TLs) are associated with increased immunogenicity and increased risk of developing complicated disease course of time. The clearance of IFX is influenced by many factors. Clearance of IFX in IBD can be influenced by disease severity (i.e., local vs. systemic inflammation), increased intestinal permeability, increased proteatic activity, the presence of antibodies to IFX (ATI), and the use of a concomitant immunomodulatory. Furthermore, the study of Dotan el al. showed that clearance of IFX is not linearly related weight, meaning that patients with lower body weight might need higher IFX doses.
Despite these data, the current dosing recommendation of IFX is still a weight-based dose (5 mg/kg) during induction (infusion at weeks 0, 2, and 6) and the maintenance phase (every 8 weeks) extrapolated from adult studies. However, recent evidence indicates that pediatric patients have a 25-40% lower drug exposure compared to adults. Particularly in children under 10 years of age, Jongsma et al. showed in a retrospective cohort a median IFX TLs at week 14 of 3.1 µg/mL in a subset of young CD patients (age \< 10 years), which is far below the recently recommended target trough level \> 5 µg/mL at week 14. Based on this data, young children probably need higher IFX dosing to obtain optimal IFX trough levels.
However, up till now no prospective trials have been performed using an intensified dosing scheme for younger CD patients. As stated above, adult data on intensified dosing schemes cannot be directly extrapolated to children due to pharmacokinetic differences. Therefore, a prospective trial within children with CD is necessary to identify a possible new dosing scheme for these patients. This study is innovative, as it will be the first prospective trial to determine if an IFX intensified induction scheme is more effective than standard dose in pediatric CD. This study will provide additional knowledge whether an intensified induction scheme in younger patients will indeed result in higher trough levels and better disease outcomes.
OBJECTIVES
The purpose of this study is to define an optimal IFX dosing schedule for patients aged 1-15 years with CD.
The primary study objective is:
- To assess the proportion of patients with IFX Trough level ≥ 5 µg/mL at week 12 without treatment escalation
The secondary objectives are:
- To assess the efficacy of an IFX intensified induction scheme in obtaining clinical and biochemical remission at weeks 4, 12, and 24 without treatment escalation.
- To assess whether an intensified induction scheme increases the frequency of ATI and/or of infusion reactions/adverse reactions.
- To assess factors that will predict who will respond to IFX based on proteomic analysis.
STUDY DESIGN
The investigators will perform an international, multicenter, prospective, open-label trial. The study duration for each individual participant will consist of a 4-week screening period and a 24-week intervention period. Patients will be enrolled over 12 months. The study will be completed in 24 months. An illustration of the study design is given in supplement 1.
STUDY POPULATION
Approximately 50 patients aged 1-15 years (30 patients aged 1-9 years and 20 patients aged 10-15 years) with CD and an indication to start IFX will be prospectively enrolled. Patients will be recruited in academic centers with specific expertise in pediatric IBD within Europe.
TREATMENT OF SUBJECTS
Investigational treatment
IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks. The choice of this intensified induction scheme was based on both preliminary modeling and experience gained from everyday clinical practice. The investigational medicinal product is infliximab (Inflectra®, Hospira, or any of the other biosimilars of IFX according to the local availability in the participating centre) administered intravenously with a more intensified induction scheme.
Use of co-intervention at the start of IFX
Patients are allowed to enter the study if they receive other drugs (co-medications) at the start of IFX. The allowed co-medications and their restrictions are as follows:
- Steroids: when started more than 2 weeks before the first IFX infusion. Patients will be instructed to follow a tapering schedule aiming at corticosteroid withdrawal by week 12.
- Mesalazine: when started more than 2 weeks before first IFX infusion, the dose should not be increased through week 24.
- EEN: when started more than 2 weeks before the first IFX infusion
- Partial Enteral Nutrition, Crohn's Disease Exclusion Diet or other dietary therapy
- Azathioprine (AZA) or methotrexate (MTX): the dose should not be increased through week 24 except for weight-based or metabolite-based adjustments. AZA/MTX can be discontinued at any time.
Escape medication
During the follow-up, there may be a need for an additional CD-related intervention, which may be indicated in the case of primary non-response, secondary LOR, or intolerance to study medication. In these situations, treatment changes will be made at the physicians' discretion, and follow-up will continue for the duration of the study (week 24).
Allowed additional CD-related treatment may be:
- Increasing dose of IFX (advised) or shortening of the interval
- Start or intensification of Exclusive or polymeric enteral nutrition
- Start or intensification of steroids (oral or topical)
- Start or intensification of immunomodulators (AZA, MTX) (except intensification based on weight or metabolites).
- Start or intensification of mesalazine (oral or topical)
- Start of antibiotics (limited to indication for CD, i.e. perianal disease)
- Start of biologics other than anti-TNF-α (including but not limited to ustekinumab, vedolizumab, abatacept, anakinra, etc.)
- Start of other CD related treatment specified in the European guideline of CD in children.
Study procedures
Screening for eligible participants will be performed within 4 weeks prior to the first IFX infusion. Before starting IFX, as part of usual clinical care patients will be screened for the following infections: tuberculosis, hepatitis B and C and Epstein-Barr virus.
If patients are included within the study, they will undergo the following study procedures:
- IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks. The choice of this intensified induction scheme was based on both preliminary modeling and experience gained from everyday clinical practice.
- Study visits will be scheduled at each IFX infusion at week 0 (baseline), 2, 4, 8, 12, and 24 (end of study). At each visit, the following parameters will be assessed: clinical disease activity (wPCDAI), weight (kg), height (cm), concomitant medication (type and dosage), IFX dosage and interval, changes in medication, adverse events, and IBD standard laboratory tests (hemoglobin, hematocrit, white blood cells, platelet count, CRP, erythrocyte sedimentation rate - ESR, albumin). wPCDAI is a validated instrument for measuring disease activity in children and adolescents with CD. This score is a mathematically weighted version of PCDAI. The wPCDAI is composed of three domains (clinical symptoms, physical examination, and laboratory variables), with individual items mathematically weighted to produce an overall score that classifies patients into 4 disease activity categories: none, \< 12.5; mild, 12.5 to 40; moderate, \> 40 to 57.5; and severe, \> 57.5. A decrease of 17.5 points is taken as evidence of improvement.
- IFX TLs will be measured at weeks 4, 12, and 24. ATI will be measured if IFX TL \< 1 µg/mL. Blood samples will be taken to determine IFX TLs and ATI. All blood samples will be taken during a routine blood draw or out of the already inserted infusion needle. For the purpose of this study, one extra tube of blood will be drawn. Blood samples for TLs and ATI will be locally stored at -80 °C and then sent to the coordinating center (Erasmus MC) to be analyzed (ELISA assay). On clinical indication, IFX TLs and ATI can also be determined locally in the participating centers.
- FC (quantitative) will be measured at baseline, week 12 and 24. FC is a non-invasive tool to evaluate mucosal healing. Assays for FC concentration will be performed using a validated method at study site laboratories.
- Quality of life will be checked in order to assess the impact on quality of life of the intensified induction scheme. It will be assessed at baseline, weeks 12, and 24. Quality of life will be assessed with the IBD-specific Impact-III score and EQ-5D-Y questionnaire.
The total duration of follow-up will be 24 weeks. During the follow-up, the IFX dose and/or interval adjustments or the IFX discontinuation will be possible on indication (i.e., primary nonresponse, secondary LOR, intolerance to study medication) at the physicians' discretion. Any adjustments will be notified to the coordinating center.
Withdrawal of individual subjects
No specific criteria for study withdrawal exist. Patients can leave the study at any time for any reason if they wish to do so without any consequences. The investigator can decide to withdraw a subject from the study for urgent medical reasons. The treating physician can deviate from the study protocol for medical reasons (i.e., persistent non-response or LOR despite adequate IFX TLs and treatment escalation, high ATI, severe infusion reactions, severe adverse reactions).
STATISTICAL ANALYSIS
Parametric variables will be described by their mean and standard deviation (SD) and compared with use of the T-test. Non-parametric variables will be described by their median and interquartile range and compared using the Mann-Whitney U test. Categorical variables will be summarized using counts and percentages. A Chi-squared test will be used for analyses without a stratification factor. All statistical testing will be 2-sided and significant at the 0.05 level. Missing data will be reported and left out of analyses. Graphical data displays (i.e., box plots) may also be used to summarize the data.
Statistical test primary endpoint:
To test whether the percentage in the study group will be different from the population, the one sample Z-test will be performed. In the RAPID cohort, 68% of patients with CD and age \<10 had trough levels \<5 ug/ml. Null hypotheses will be that percentage of patients with trough level \>5 ug/ml without treatment escalation will be similar to (100%-68%=) 32% (based on outcomes of the RAPID cohort). Alternative hypothesis will be that percentage will be different from 32%. The assumptions that will be tested are the following: p · n ≥ 10 and (1 - p) · n ≥ 10. If these assumptions are not met, the proportion of patients reaching the primary endpoint will be tested by the non-parametric one sample Binomial Test.
- Conditions
- Crohn Disease, Child, Only, Biologic; Inadequate
- Being tested
- Infliximab
- Medical subject headings
- Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InfliximabDrug
IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion.
| Study group | Role | What they receive |
|---|---|---|
| Intensified induction scheme with Infliximab | Experimental | Intensified induction scheme with Infliximab. IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks. Receives: Drug: Infliximab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients with IFX Trough Levels ≥ 5 µg/mL at week 12 without treatment escalation
Treatment escalation is defined as any additional CD-related medication or IBD-related abdominal surgery
Measured: 12 weeks
Secondary outcomes (6)
Proportion of patients with IFX Trough Levels ≥ 5 µg/mL at week 24 without the need for treatment escalation
Treatment escalation is defined as any additional CD-related medication or IBD-related abdominal surgery
Measured: 24 weeks
Clinical and biochemical remission at weeks 4, 12, and 24 without the need for treatment escalation in patients with TL ≥ 5 µg/mL and in patients with TL < 5 µg/mL.
Clinical remission is defined as wPCDAI <12.5 Biochemical remission is defined as CRP <5 mg/dL, FC <250 ug/g.
Measured: 24 weeks
Predictors of IFX Trough Levels at weeks 4, 12, and 24. Factors included in this analysis will be sex, age, body mass index (BMI), wPCDAI, IBD laboratory values, antibodies to Infliximab (ATI), dose, and interval of IFX infusions.
Measured: 24 weeks
Development of antibodies to IFX until week 24
ATI's will be assessed if IFX TL is <1 ug/ml at week 4, 12 or 24.
Measured: 24 weeks
Prediction of reponders versus non-responders to IFX based on proteomic analysis.
Responders will be defined as decrease of 17.5 in wPCDAI at week 6 from start of IFX. Serum immune proteins will be analysed using the OLINK technique. It will be investigated whether there are predictive immune proteins of IFX response
Measured: 24 weeks
Evaluation of quality of life
Quality of life will be assessed at baseline, weeks 12 and 24 in all patients.
Measured: 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2022
- Study start2 Aug 2023
- Primary completionAug 2025 (estimated)
- Study completionAug 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Crohn DiseaseStudies of the same condition, open and under way.
- More trials run by Erasmus Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Erasmus Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lissy de Ridder, Erasmus Medical Center
- Investigators
- Lissy de Ridder, PhD, Principal investigator, Erasmus Medical Center - Sophia Children's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05552287
- Sponsor's protocol ID
- ProRAPID
- Acronym
- ProRAPID
- Status last verified
- Sep 2024
- First submitted
- 11 Jul 2022
- Last updated
- 19 Sep 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Analysis of Pharmacokinetic Infliximab Data in Pediatric CD Patients (ProRAPID)
- ClinicalTrials.gov ID
- NCT05552287
- Acronym / sponsor ID
- ProRAPID / ProRAPID
- Conditions
- Crohn Disease, Child, Only, Biologic; Inadequate
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Erasmus Medical CenterUniversity, hospital or other
- Study start
- 2 Aug 2023 (actual)
- Primary completion
- Aug 2025 (estimated)
- Study completion
- Aug 2025 (estimated)
- First posted
- 23 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale: Crohn's disease (CD) is a chronic, debilitating inflammatory bowel disease (IBD) which is diagnosed during childhood in up to one in ten patients. The use of anti-tumor necrosis factor (TNF)-α agents has significantly ameliorated CD management. Infliximab (IFX) is the first anti-TNF-α agent registered for pediatric CD. The current dosing recommendation of IFX is extrapolated from adult studies, and it is a weight-based dose (5 mg/kg) delivered during induction (infusion at weeks 0, 2, and 6) and maintenance (every 8 weeks). However, pediatric patients have a 25-40% lower drug exposure compared to adults, particularly children under 10 years of age, resulting in diminished efficacy and an increased risk of developing a complicated disease course. The investigators hypothesize that an intensified IFX induction scheme (instead of the current dosing recommendation) is more effective in the treatment of pediatric CD patients.
Objective: The primary study objective of our study is to assess the efficacy of an IFX intensified induction scheme vs. a standard dosing schedule in improving drug exposure without treatment escalation in pediatric CD patients. Secondary objectives are clinical and biochemical remission without treatment escalation, development of antibodies to IFX (ATI) and adverse reactions.
Study design: An international, multicenter, prospective, open-label trial. Study population: Anti-TNF-α naïve children (age 1-15 years) with CD and an indication to start IFX treatment.
Intervention: IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion. Follow-up will continue for the duration of the study (week 24).
Main endpoint: Proportion of patients with IFX TL ≥ 5 µg/mL at week 12 without treatment escalation.
Detailed description
INTRODUCTION AND RATIONALE
Definition of the problem
Crohn's disease (CD) is a chronic, debilitating inflammatory bowel disease (IBD) which is diagnosed during childhood in up to one in ten patients. Pediatric CD patients often have more severe and extensive disease compared to adults. Prospective studies in pediatric CD are scarce; therefore, many questions remain unanswered in the treatment of pediatric CD. The discovery of anti-tumor necrosis factor (TNF)-α agents opened up a new window in the pharmacological management of this condition. Infliximab (IFX) was the first anti-TNF-α agent to be approved for use in the treatment of CD. Several clinical studies showed its efficacy in inducing mucosal healing and improving long-term outcomes, even as a first-line treatment. Efficacy of IFX has been related to IFX trough levels, which are dependent on clearance of IFX. Lower IFX trough levels (TLs) are associated with increased immunogenicity and increased risk of developing complicated disease course of time. The clearance of IFX is influenced by many factors. Clearance of IFX in IBD can be influenced by disease severity (i.e., local vs. systemic inflammation), increased intestinal permeability, increased proteatic activity, the presence of antibodies to IFX (ATI), and the use of a concomitant immunomodulatory. Furthermore, the study of Dotan el al. showed that clearance of IFX is not linearly related weight, meaning that patients with lower body weight might need higher IFX doses.
Despite these data, the current dosing recommendation of IFX is still a weight-based dose (5 mg/kg) during induction (infusion at weeks 0, 2, and 6) and the maintenance phase (every 8 weeks) extrapolated from adult studies. However, recent evidence indicates that pediatric patients have a 25-40% lower drug exposure compared to adults. Particularly in children under 10 years of age, Jongsma et al. showed in a retrospective cohort a median IFX TLs at week 14 of 3.1 µg/mL in a subset of young CD patients (age \&lt; 10 years), which is far below the recently recommended target trough level \&gt; 5 µg/mL at week 14. Based on this data, young children probably need higher IFX dosing to obtain optimal IFX trough levels.
However, up till now no prospective trials have been performed using an intensified dosing scheme for younger CD patients. As stated above, adult data on intensified dosing schemes cannot be directly extrapolated to children due to pharmacokinetic differences. Therefore, a prospective trial within children with CD is necessary to identify a possible new dosing scheme for these patients. This study is innovative, as it will be the first prospective trial to determine if an IFX intensified induction scheme is more effective than standard dose in pediatric CD. This study will provide additional knowledge whether an intensified induction scheme in younger patients will indeed result in higher trough levels and better disease outcomes.
OBJECTIVES
The purpose of this study is to define an optimal IFX dosing schedule for patients aged 1-15 years with CD.
The primary study objective is:
- To assess the proportion of patients with IFX Trough level ≥ 5 µg/mL at week 12 without treatment escalation
The secondary objectives are:
- To assess the efficacy of an IFX intensified induction scheme in obtaining clinical and biochemical remission at weeks 4, 12, and 24 without treatment escalation.
- To assess whether an intensified induction scheme increases the frequency of ATI and/or of infusion reactions/adverse reactions.
- To assess factors that will predict who will respond to IFX based on proteomic analysis.
STUDY DESIGN
The investigators will perform an international, multicenter, prospective, open-label trial. The study duration for each individual participant will consist of a 4-week screening period and a 24-week intervention period. Patients will be enrolled over 12 months. The study will be completed in 24 months. An illustration of the study design is given in supplement 1.
STUDY POPULATION
Approximately 50 patients aged 1-15 years (30 patients aged 1-9 years and 20 patients aged 10-15 years) with CD and an indication to start IFX will be prospectively enrolled. Patients will be recruited in academic centers with specific expertise in pediatric IBD within Europe.
TREATMENT OF SUBJECTS
Investigational treatment
IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks. The choice of this intensified induction scheme was based on both preliminary modeling and experience gained from everyday clinical practice. The investigational medicinal product is infliximab (Inflectra®, Hospira, or any of the other biosimilars of IFX according to the local availability in the participating centre) administered intravenously with a more intensified induction scheme.
Use of co-intervention at the start of IFX
Patients are allowed to enter the study if they receive other drugs (co-medications) at the start of IFX. The allowed co-medications and their restrictions are as follows:
- Steroids: when started more than 2 weeks before the first IFX infusion. Patients will be instructed to follow a tapering schedule aiming at corticosteroid withdrawal by week 12.
- Mesalazine: when started more than 2 weeks before first IFX infusion, the dose should not be increased through week 24.
- EEN: when started more than 2 weeks before the first IFX infusion
- Partial Enteral Nutrition, Crohn's Disease Exclusion Diet or other dietary therapy
- Azathioprine (AZA) or methotrexate (MTX): the dose should not be increased through week 24 except for weight-based or metabolite-based adjustments. AZA/MTX can be discontinued at any time.
Escape medication
During the follow-up, there may be a need for an additional CD-related intervention, which may be indicated in the case of primary non-response, secondary LOR, or intolerance to study medication. In these situations, treatment changes will be made at the physicians' discretion, and follow-up will continue for the duration of the study (week 24).
Allowed additional CD-related treatment may be:
- Increasing dose of IFX (advised) or shortening of the interval
- Start or intensification of Exclusive or polymeric enteral nutrition
- Start or intensification of steroids (oral or topical)
- Start or intensification of immunomodulators (AZA, MTX) (except intensification based on weight or metabolites).
- Start or intensification of mesalazine (oral or topical)
- Start of antibiotics (limited to indication for CD, i.e. perianal disease)
- Start of biologics other than anti-TNF-α (including but not limited to ustekinumab, vedolizumab, abatacept, anakinra, etc.)
- Start of other CD related treatment specified in the European guideline of CD in children.
Study procedures
Screening for eligible participants will be performed within 4 weeks prior to the first IFX infusion. Before starting IFX, as part of usual clinical care patients will be screened for the following infections: tuberculosis, hepatitis B and C and Epstein-Barr virus.
If patients are included within the study, they will undergo the following study procedures:
- IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks. The choice of this intensified induction scheme was based on both preliminary modeling and experience gained from everyday clinical practice.
- Study visits will be scheduled at each IFX infusion at week 0 (baseline), 2, 4, 8, 12, and 24 (end of study). At each visit, the following parameters will be assessed: clinical disease activity (wPCDAI), weight (kg), height (cm), concomitant medication (type and dosage), IFX dosage and interval, changes in medication, adverse events, and IBD standard laboratory tests (hemoglobin, hematocrit, white blood cells, platelet count, CRP, erythrocyte sedimentation rate - ESR, albumin). wPCDAI is a validated instrument for measuring disease activity in children and adolescents with CD. This score is a mathematically weighted version of PCDAI. The wPCDAI is composed of three domains (clinical symptoms, physical examination, and laboratory variables), with individual items mathematically weighted to produce an overall score that classifies patients into 4 disease activity categories: none, \&lt; 12.5; mild, 12.5 to 40; moderate, \&gt; 40 to 57.5; and severe, \&gt; 57.5. A decrease of 17.5 points is taken as evidence of improvement.
- IFX TLs will be measured at weeks 4, 12, and 24. ATI will be measured if IFX TL \&lt; 1 µg/mL. Blood samples will be taken to determine IFX TLs and ATI. All blood samples will be taken during a routine blood draw or out of the already inserted infusion needle. For the purpose of this study, one extra tube of blood will be drawn. Blood samples for TLs and ATI will be locally stored at -80 °C and then sent to the coordinating center (Erasmus MC) to be analyzed (ELISA assay). On clinical indication, IFX TLs and ATI can also be determined locally in the participating centers.
- FC (quantitative) will be measured at baseline, week 12 and 24. FC is a non-invasive tool to evaluate mucosal healing. Assays for FC concentration will be performed using a validated method at study site laboratories.
- Quality of life will be checked in order to assess the impact on quality of life of the intensified induction scheme. It will be assessed at baseline, weeks 12, and 24. Quality of life will be assessed with the IBD-specific Impact-III score and EQ-5D-Y questionnaire.
The total duration of follow-up will be 24 weeks. During the follow-up, the IFX dose and/or interval adjustments or the IFX discontinuation will be possible on indication (i.e., primary nonresponse, secondary LOR, intolerance to study medication) at the physicians' discretion. Any adjustments will be notified to the coordinating center.
Withdrawal of individual subjects
No specific criteria for study withdrawal exist. Patients can leave the study at any time for any reason if they wish to do so without any consequences. The investigator can decide to withdraw a subject from the study for urgent medical reasons. The treating physician can deviate from the study protocol for medical reasons (i.e., persistent non-response or LOR despite adequate IFX TLs and treatment escalation, high ATI, severe infusion reactions, severe adverse reactions).
STATISTICAL ANALYSIS
Parametric variables will be described by their mean and standard deviation (SD) and compared with use of the T-test. Non-parametric variables will be described by their median and interquartile range and compared using the Mann-Whitney U test. Categorical variables will be summarized using counts and percentages. A Chi-squared test will be used for analyses without a stratification factor. All statistical testing will be 2-sided and significant at the 0.05 level. Missing data will be reported and left out of analyses. Graphical data displays (i.e., box plots) may also be used to summarize the data.
Statistical test primary endpoint:
To test whether the percentage in the study group will be different from the population, the one sample Z-test will be performed. In the RAPID cohort, 68% of patients with CD and age \&lt;10 had trough levels \&lt;5 ug/ml. Null hypotheses will be that percentage of patients with trough level \&gt;5 ug/ml without treatment escalation will be similar to (100%-68%=) 32% (based on outcomes of the RAPID cohort). Alternative hypothesis will be that percentage will be different from 32%. The assumptions that will be tested are the following: p · n ≥ 10 and (1 - p) · n ≥ 10. If these assumptions are not met, the proportion of patients reaching the primary endpoint will be tested by the non-parametric one sample Binomial Test.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intensified induction scheme with Infliximab | Experimental | Drug: InfliximabIntensified induction scheme with Infliximab. IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks. |
Who may qualify
- Ages
- 1 year to 15 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Anti-TNF-α naïve children (age 1-15 years) with CD and an indication to start IFX treatment will be eligible for inclusion after a diagnosis of CD is made based on the Porto criteria. Indications of starting IFX treatment as per ECCO-ESPGHAN guidelines include non-response after induction with exclusive enteral nutrition or steroids, non-response to immunomodulators, severe growth delay, extensive disease and/or structuring or penetrating disease, with or without perianal disease. Evaluation of the indication to start IFX is performed at the discretion of the attending physician.
Key exclusion criteria (10 listed)
- Established monogenetic IBD
- Diagnosis with UC or IBD-U, ulcerative colitis like
- Active fistulizing/perianal disease at start of IFX treatment (patients with inactive fistulizing/perianal disease are allowed to participate)
- Severe comorbidity (not related to IBD)
- Immediate need for surgery (i.e., symptomatic stenosis or stricture in the bowel)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InfliximabIFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion. | Drug | Intensified induction scheme with Infliximab |
Primary outcome
Proportion of patients with IFX Trough Levels ≥ 5 µg/mL at week 12 without treatment escalation
Time frame: 12 weeks
Treatment escalation is defined as any additional CD-related medication or IBD-related abdominal surgery
6 secondary outcomes
Proportion of patients with IFX Trough Levels ≥ 5 µg/mL at week 24 without the need for treatment escalation
Time frame: 24 weeks
Clinical and biochemical remission at weeks 4, 12, and 24 without the need for treatment escalation in patients with TL ≥ 5 µg/mL and in patients with TL < 5 µg/mL.
Time frame: 24 weeks
Predictors of IFX Trough Levels at weeks 4, 12, and 24. Factors included in this analysis will be sex, age, body mass index (BMI), wPCDAI, IBD laboratory values, antibodies to Infliximab (ATI), dose, and interval of IFX infusions.
Time frame: 24 weeks
Development of antibodies to IFX until week 24
Time frame: 24 weeks
Prediction of reponders versus non-responders to IFX based on proteomic analysis.
Time frame: 24 weeks
Evaluation of quality of life
Time frame: 24 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Sep 2024.
- Individual participant dataSharing planned: No
Related trials for Crohn Disease
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lissy de Ridder, PhD principal investigator
Erasmus Medical Center - Sophia Children's Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Infliximab in people with Crohn Disease and Child, Only, run by Erasmus Medical Center at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Lissy de Ridder, PhD (0107036076, l.deridder@erasmusmc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients with IFX Trough Levels ≥ 5 µg/mL at week 12 without treatment escalation (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2024.